Related Experiment Video
Updated: May 23, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Protein C anticoagulant and cytoprotective pathways
John H Griffin1, Berislav V Zlokovic, Laurent O Mosnier
1Department of Molecular and Experimental Medicine, MEM-180, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. jgriffin@scripps.edu
International Journal of Hematology
|April 6, 2012
Summary
Activated protein C (APC) is a vital enzyme with anticoagulant and cytoprotective effects. Deficiencies increase thrombosis risk, while APC shows promise in treating conditions like ischemic stroke.
Area of Science:
- Biochemistry
- Hematology
- Cell Biology
Background:
- Protein C is a serine protease zymogen converted to activated protein C (APC).
- APC plays a crucial role in anticoagulation by inactivating factors Va and VIIIa.
- Deficiencies in Protein C or Protein S are linked to thrombosis and purpura fulminans.
Purpose of the Study:
- To review the molecular mechanisms of the protein C pathway.
- To explore the link between protein C pathway deficiencies and venous thrombosis.
- To summarize the cytoprotective and neuroprotective effects of APC.
Main Methods:
- Literature review of protein C pathway molecules and functions.
- Analysis of the relationship between genetic deficiencies and thrombosis risk.
- Examination of APC's cell-mediated signaling and therapeutic potential.
Main Results:
- APC's anticoagulant activity is enhanced by protein S, lipids, and factor V.
- APC exhibits significant cytoprotective effects in preclinical injury models.
- Pharmacologic APC therapy demonstrates neuroprotective benefits, particularly in ischemic stroke models.
Conclusions:
- The protein C pathway is critical for hemostasis and cellular protection.
- APC's multifaceted actions, including anticoagulation and cytoprotection, highlight its therapeutic potential.
- Further research into APC signaling pathways may yield novel treatments for thrombotic and neurological disorders.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...